Sinopharm protein-based booster stronger against Omicron than earlier shot

A protein-based Covid-19 booster vaccine made by Sinopharm elicited a stronger antibody response against the Omicron variant when given as a booster after two doses of an earlier shot from the Chinese firm than a third dose of the original, a study showed.The study which was published on Tuesday and had not been peer reviewed, came amid concerns over the effectiveness of Sinopharm’s BBIBP-CorV shot, one of the two leading Covid-19 vaccines exported by China, against the Omicron variant.An…

Read the original article at South China Morning Post